FDA to review Actelion's macitentan for PAH

Actelion Ltd. (SIX:ATLN) said FDA accepted for review an NDA for Opsumit macitentan to treat pulmonary arterial hypertension. Actelion submitted the NDA in October. The company said the review period ...